Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BTOG 2023 | The benefits of immunotherapy versus chemotherapy: analyzing the results of the IPSOS trial

Riyaz Shah, BSc(Hons), MBBS, FRCP, PhD, Kent Oncology Centre, Maidstone, UK, summarizes the findings from the Phase III IPSOS trial (NCT03191786) and the benefits of immunotherapy over chemotherapy. Despite past studies, such as the Phase III KEYNOTE-024 (NCT02142738) and KEYNOTE-042 (NCT02220894) trials recruiting performance status (PS) 1 patients, many patients with lung cancer have significant co-morbidities, and do not meet the reimbursement criteria for immunotherapy. The IPSOS trial allowed for the definition of single agent chemotherapy as being a potential treatment option. Additionally, patients were recruited with significant co-morbidities and randomised them to either atezolizumab or chemotherapy. Immunotherapy was found to provide a survival benefit that was greater than chemotherapy, with some patients undergoing chemotherapy going on to receive immunotherapy. This interview took place at the British Thoracic Oncology Group (BTOG) Annual Conference 2023 in Belfast, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.